Showing results (11-20 of 90) with videos related to

Sort By:
Pageof 9
EJNMMI Physics|January 12, 2020
Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF)Julian M Rogasch, Said Suleiman, Frank Hofheinz, et al.
BMC Cancer|May 5, 2018
Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphomaJulian M M Rogasch, Patrick Hundsdoerfer, Frank Hofheinz, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 18, 2018
68 Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancerJonathan Damjanovic, Jan-Carlo Janssen, Christian Furth, et al.
Expert Review of Anticancer Therapy|September 15, 2010
The role of PET in Hodgkin's lymphoma and its impact on radiation oncologyCarsten Kobe, Markus Dietlein, Jan Kriz, et al.
Physics in Medicine and Biology|April 6, 2021
Respiratory motion correction for enhanced quantification of hepatic lesions in simultaneous PET and DCE-MR imagingMatteo Ippoliti, Mathias Lukas, Winfried Brenner, et al.
Clinical Nuclear Medicine|December 19, 2018
Point Spread Function Reconstruction for Integrated 18F-FET PET/MRI in Patients With Glioma: Does It Affect SUVs and Respective Tumor-to-Background Ratios?Julian Manuel Michael Rogasch, Josefine Albers, Ferdinand L Steinkrüger, et al.
Cancers|February 10, 2021
The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective AnalysisTristan Ruhwedel, Julian M M Rogasch, Kai Huang, et al.
Frontiers in Oncology|May 9, 2022
Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer PatientsSebastian Zschaeck, Stephanie Bela Andela, Holger Amthauer, et al.
Radiation Oncology (London, England)|August 24, 2017
Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patientsSebastian Zschaeck, Peter Wust, Marcus Beck, et al.
Diagnostics (Basel, Switzerland)|September 25, 2020
Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?Christoph Wetz, Julian Rogasch, Philipp Genseke, et al.
Pageof 9